Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 14/20 | 0.55 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | CASP1 | P29466 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22466080 | 1.00 | ERN1 (0.55) | ERN1PTPN1ALOX15TSHRCASP1 | |
| SCHEMBL29377386 | 0.95 | PTPN1 (0.56) | ERN1PTPN1ALOX15TSHRCASP1 | |
| SCHEMBL22466175 | 0.95 | PTPN1 (0.56) | ERN1PTPN1ALOX15TSHRCASP1 | |
| SCHEMBL22466112 | 0.82 | ERN1 (0.45) | ERN1 | |
| SCHEMBL29549647 | 0.82 | ERN1 (0.45) | ERN1 | |
| SCHEMBL22465967 | 0.82 | ERN1 (0.56) | ERN1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL29549605 | 0.82 | ERN1 (0.56) | ERN1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL22466106 | 0.78 | ERN1 (0.45) | ERN1PTPN1 | |
| SCHEMBL29549603 | 0.78 | ERN1 (0.45) | ERN1PTPN1 | |
| SCHEMBL22466081 | 0.77 | ERN1 (0.43) | ERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114025847-B | Compounds and compositions as modulators of TLR signaling | 神经孔疗法股份有限公司 | 2024-05-24 | — | — | CN | disclosed |
| US-20220298155-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF TLR SIGNALING | NEUROPORE THERAPIES, INC. (US) | 2022-09-22 | — | — | US | disclosed |
| US-11299487-B2 | Compounds and compositions as modulators of TLR signaling | NEUROPORE THERAPIES, INC. (US) | 2022-04-12 | — | — | US | disclosed |
| CN-114025847-A | Compounds and compositions as modulators of TLR signaling | 神经孔疗法股份有限公司 | 2022-02-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220298155-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF TLR SIGNALING | TLR3, TLR6, TLR4 | ERN1 738/4885PTPN1 924/4885ALOX15 1609/4885 |
| US-11299487-B2 | Compounds and compositions as modulators of TLR signaling | TLR3, TLR6, TLR4 | ERN1 840/4885PTPN1 734/4885ALOX15 1693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.